Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.
The Thoracic Cancer Research and Detection Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel. nirp@post.tau.ac.il
Nir
N
Peled
Gary
G
Palmer
Fred R
FR
Hirsch
Murry W
MW
Wynes
Maya
M
Ilouze
Marileila
M
Varella-Garcia
Lior
L
Soussan-Gutman
Geoff A
GA
Otto
Philip J
PJ
Stephens
Jeffrey S
JS
Ross
Maureen T
MT
Cronin
Doron
D
Lipson
Vincent A
VA
Miller
D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics* / Q000556:secondary; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics* / Q000556:secondary; D000077547:Crizotinib; D015321:Gene Rearrangement / Q000187:drug effects*; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D008297:Male; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
D000970:Antineoplastic Agents; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases